Moleculin Biotech Files 8-K Report
Ticker: MBRX · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1659617
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: MBRX
TL;DR
Moleculin Biotech filed an 8-K, likely containing financial updates. Keep an eye out for details.
AI Summary
On September 25, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Moleculin Biotech, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's financial status or regulatory compliance.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial data that would indicate immediate risk.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- September 25, 2025 (date) — Date of Report
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Moleculin Biotech, Inc.?
The filing is primarily for Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the Item Information section.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 25, 2025.
Where are Moleculin Biotech, Inc.'s principal executive offices located?
The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the company's telephone number as listed in the filing?
The company's telephone number is (713) 300-5160.
What is the Standard Industrial Classification (SIC) code for Moleculin Biotech, Inc.?
The Standard Industrial Classification code for Moleculin Biotech, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-09-25 08:35:09
Filing Documents
- mbrx20250923_8k.htm (8-K) — 26KB
- ex_864341.htm (EX-99.1) — 10KB
- a01.jpg (GRAPHIC) — 10KB
- 0001437749-25-029847.txt ( ) — 198KB
- mbrx-20250925.xsd (EX-101.SCH) — 3KB
- mbrx-20250925_def.xml (EX-101.DEF) — 12KB
- mbrx-20250925_lab.xml (EX-101.LAB) — 15KB
- mbrx-20250925_pre.xml (EX-101.PRE) — 12KB
- mbrx20250923_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On September 25, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of intent to grant for Patent Application No. 3,142,510 titled " PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE. " A patent from the application is expected to be issued in the coming months. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated September 25, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: September 25, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster